Life-enhancing breast healthcare products development company CYduct Diagnostics Inc (OTCMKTS:CYDX) announced yesterday that it had recently attended a key industry event. The event question was the 11th International Symposium on the Human Breast hosted by Dr. Susan Love Foundation for Breast Cancer Research.
On Wednesday, CYDX stock ended flat at $0.7500 with more than 1K shares, compared to its average volume of 101 shares. The stock moved within a range of $0.7500 – 0.7500 after opening trade at $0.7500.
CYduct Diagnostics Inc. Clinical Team Wins Grant and Takes the Stage at the Dr. Susan Love Foundation’s 11th International Symposium on the Human Breast
It is one of the more important events that is focussed on making further advancements in the area of breast health. At that event, the clinical team at CYduct was also bestowed with a prestigious grant award for its work in relation to risk assessment for breast cancer. The grant is awarded by the Sharon D Lund Foundation.
The grant will help the clinical team at CYduct to collaborate with some of the leading advisory groups in the field of breast cancer, so as to continue with the development of a potentially game changing proteomic breast cancer risk assessment test.
The test that the clinical team would work on would deploy targeted biomarkers which are related to the progression of breast cancer. At the event, the members of the clinical team at the company made a presentation with regards to its simple and non-invasive breast cancer risk assessment test.